New drug aims to help tiniest babies absorb nutrients safely

NCT ID NCT05904626

Recruiting now Disease control Sponsor: Elgan Pharma Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called ELGN-2112 in 60 very premature infants (born before 26 weeks) and growth-restricted infants (born 26-32 weeks). The goal is to see if the drug is safe compared to a placebo. If it works, it could help these fragile babies absorb nutrients better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ELGN-2112

What this could lead to

If successful, this could point toward a safe treatment to help preterm and growth-restricted infants absorb nutrients better.

What could go wrong

This is an early Phase 2 safety study with only 60 infants, so it may not show clear benefit. The drug could still have side effects not yet seen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates